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The pharmacological treatment of neoplasia is based on the use of chemotherapeutic
substances. Chemotherapeutic agents can cause acute and chronic toxicity even at ther-
apeutic doses. For this reason their overdose puts a patient’s life at severe risk. This
work presents an unusual fatal case of overdose subsequent to an accidental massive
administration of Vinblastine (90 mg instead of 9 mg), slow bolus (ﬁve minutes), to a
33-year-old woman who suffered from Hodgkin’s Lymphoma. The administration of
the massive dose was due to a transcription error of the therapeutic treatment plan and
miscommunication between the health professionals which caused the use of the wrong
dose. The forensic investigation showed the systemic macroscopic and histological
changes due to the toxic effect of Vinblastine on the body, by offering a realistic exam-
ple of the microscopic tissue changes caused by the antineoplastic agent to different
organs. Such evidence shows the importance of being very accurate when writing the
therapeutic treatment plans and of counting on adequately-trained health care staff.
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1. Introduction
Vinblastine (VBL) is a vinca alkaloid whose antineoplastic effect consists of stopping
cancer cell division by inhibiting the formation of microtubules in the mitotic spindle.
VBL is a chemotherapeutic agent commonly used in combination with other drugs
when treating some pathologies such as Hodgkin’s Lymphoma, lymphocytic and histio-
cytic lymphoma, testicle carcinoma and Kaposi’s Sarcoma.
The most common side effects are nausea, vomiting, myelosuppression and conse-
quently leucopenia, anaemia and thrombocytopenia.
Vinblastine used in combination with substances such as cisplatin, interferon, itra-
conazole and methotrexate can produce an accentuation of the cytotoxic effect especially
on the myocardium and on the nervous system. In addition, the VBL used in association
with mitomycin C can determine pulmonary toxicity and acute respiratory distress.
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The overdose of VBL causes the worsening of side effects above all leucopenia,
and in some cases neurotoxicity with paraesthesia; therefore, since there is no antidote,
it is important that the symptomatic and support treatment are started as early.
In the literature there are only few cases of VBL1–4 overdose described and just
one fatal event5; thus, below we report a case of fatal VBL poisoning that occurred
after the administration of a massive dose.
2. Case report
A 33-year-old woman suffering from nodular sclerosis Hodgkin’s lymphoma went to
the hospital to undergo the second chemotherapy treatment. According to the therapeu-
tic treatment plan there was expected to be an infusion of 37 mg of Doxorubicin, 15 IU
of Bleomycin, 555 ng of Deticene and 9 mg of Vinblastine. Due to a transcription error
on the therapeutic treatment plan, 90 mg of Vinblastine were slow bolus (ﬁve minutes)
administered into the vein. Four hours later the medical staff, after having realised the
error, called the woman back to the hospital and hospitalised her. The patient showed
copious diarrhoea, vomiting and abdominal colic; a symptomatic and support treatment
was set up with granulocyte-colony stimulating factor, detoxicants, anti-emetics and
antibiotics. Four days later the patient developed mucositis, arthralgia, fever and severe
pancytopenia. After 11 days the patient showed clear skin manifestations such as facial
erythema, bullous erythrodysesthesia to the hands and purpura. Two weeks later the
amount of white blood cells was 0.26 ×103/μL, the body temperature was 41°C and
the patient manifested clear neurotoxic effects such as hallucinations, delirium and
epileptic seizures. A thorax CT scan showed an intralobular septal thickening, ground-
glass opacity of lungs, pleuric and pericardial effusion. 16 days later a brain CT scan
showed the presence of a cerebral oedema that was getting progressively worse to
cause, 22 days later, the patient’s death. Therefore an autopsy was arranged.
2.1. Post-mortem and histological results
The autopsy showed some desquamated lesions in the oral cavity and at perioral level
with some scabby areas, areas of limb bullous erythrodysesthesia, areas of desquama-
tion on the trunk and areas of necrosis on ﬁngers. The encephalon showed a severe
oedema and vascular congestion. The heart showed several petechiae in the area of the
left ventricle wall, above all at papillary muscles level. Both lungs showed congestion
and multiple whitish dot-like lumps. The stomach showed some areas of mucosa ero-
sion. The remaining abdominal organs were congested.
During the autopsy some cutis, organs and spinal nerves were sampled to further
perform the histological examination by means of the usual technique (Haematoxylin
and Eosin staining). The encephalon showed congestion, intravascular coagulation
micro-centres of infection and perivascular micro-haemorrhages (Figure 1). The spinal
nerves showed an axonal degeneration (Figure 2). The lungs examination showed an
intra-alveolar oedema alternating with areas of massive exudation of granulocytes,
pneumocytes and hyaline pseudomembranes and areas of intra-alveolar haemorrhage;
purulent bronchitis and red-hepatizing bronchopneumonial foci (Figure 3). The heart
showed multiple areas of intravascular coagulation with coagulative necrosis foci asso-
ciated with interstitial lymphohistiocytic inﬂammation (Figure 4). The gastric and duo-
denal mucosa showed some areas of erosive inﬂammation. The liver showed a
widespread hepatic necrosis with marked lipidosis and bile stagnation (Figure 5).
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The skin takings showed an acute and subacute dermatitis with some bullous and ero-
sive signs and widespread hypoderm haemorrhages (Figure 6).
3. Discussion
The post-mortem diagnosis of systemic toxicity due to a massive dose of Vinblastine
(ten times higher than the one prescribed in this speciﬁc case) was based on the medi-
cal history, on laboratory ﬁndings, especially the severe pancytopenia, and on the post-
mortem and histological results. Such results showed an evident case of tissue damage
due to the toxic effects of VBL at cutis level6,7 and at parenchyma level, such as ence-
phalon, spinal marrow, lungs, heart, gastric mucose and liver.
The error in managing the chemotherapeutic drugs produces speciﬁc hazards linked
both to the restricted therapeutic index of such drugs, and to the toxicity that they man-
ifest also at therapeutic doses8.
Figure 1. Brain: perivascular micro-haemorrhages (a) (arrow; H&E stain 100× magniﬁcation;
scale bar, 50 μm); (b) congestion, intravascular coagulation and septic microfoci (insert) (H&E
stain 50× magniﬁcation; scale bar, 100 μm).
Figure 2. Axonal degeneration of the spinal nerves: (a) detail of reduced myelin thickness,
onion bulb formations and various stages of myelin degeneration/debris (arrows) (H&E stain at
400× magniﬁcation; scale bar, 50 μm); (b) the same microscopic ﬁeld showing positive
immunophenotype for activated CD68 microglia (arrow) (PAP method 40× magniﬁcation; scale
bar, 50 μm).
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The most severe side effects of VBL at a standard therapeutic dose, 4-6 mg/m2,
affect the bone marrow, the mucosae, the kidneys, and the gastrointestinal apparatus,
and in some cases also the central and peripheral nervous system.
Figure 3. (a) Microphotograph of intra-alveolar haemorrhage (asterisk) (H&E stain 100× magni-
ﬁcation; scale bar, 50 μm); (b) intra-alveolar oedema alternated with areas of massive granulo-
cytes exudation, pneumocytes and hyaline pseudomembranes (arrow) (H&E stain at 100×
magniﬁcation; scale bar, 50 μm).
Figure 4. Myocardial samples: (a) intravascular coagulation (asterisk) (H&E stain 200× magniﬁ-
cation; scale bar, 50 μm); (b) coagulative necrosis foci (H&E stain at 50× magniﬁcation; scale
bar, 100 μm); (c) mixed inﬂammatory cellular inﬁltration of myocardial interstitium (arrows)
(H&E stain at 100× magniﬁcation; scale bar, 50 μm).
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The VBL overdose causes a worsening of side effects with an intensiﬁcation of the
myelosuppression and a higher degree of probability of neurotoxicity. Therefore, as for
any other pharmacological substance, above all the antineoplastic drugs, the side-effect
worsening and the probability of systemic toxicity are directly proportional to the quan-
tity of administered VBL. In fact, the bigger the dose of administered VBL, the greater
the toxic effect on the body and the lower the chances of survival.
Such data are clearly documented by the presented case in which the massive dose
of VBL caused the systemic toxic effects, refractory to support therapy, that brought
about the woman’s death. In particular the 90 mg of VBL caused the anatomo-
functional damage to the encephalon, to the peripheral nervous system, to lungs, liver,
cutis, mucosae and to the hematopoietic system pointed out by the clinical course, by
the laboratory examinations, by the post-mortem and histological examination results.
The case at issue demonstrates the serious inherent risk of using VBL and, in gen-
eral, of all antineoplastic drugs. Unfortunately, this is the class of substances, together
with antibiotics, which is more susceptible of errors.
It has been estimated that the errors linked to chemotherapeutic treatment represent
15.6% of therapeutic errors, 21% of which are due to a wrong transcription of the ther-
apeutic treatment plan while 38% to the administration of wrong doses9–11.
The cases of overdose of the most signalled chemotherapeutic drugs concern
methotrexate, cisplatin, oxaliplatin, imatinib, and vincristine12–18. Although fatal events
are rare, the systemic toxic effects documented by the presented case highlight the fact
that the activities of the health care staff involved in the chemotherapeutic treatment
are burdened by potentially lethal risks for patients.
The management of the chemotherapeutic agents is very important in the ordering,
preparation and administration phases. Moreover, in order to avoid such adverse events,
Figure 5. Microscopic liver panlobular collapse (400× magniﬁcation) showing hepatocellular
necrosis, marked lipidosis (asterisks) and bile concentration (insert) (H&E stain; scale bar,
50 μm).
708 E.Ventura Spagnolo et al.
D
ow
nl
oa
de
d 
by
 [9
3.4
6.6
5.1
76
] a
t 2
3:3
4 1
2 O
cto
be
r 2
01
7 
the importance of communication among the staff members and the accurate set up of
the therapeutic treatment plan, as well as the adequate training of nurses who check the
dose of drugs and administer them should be emphasised.
Disclosure statement
No potential conﬂict of interest was reported by the authors.
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